报价延迟最少15分钟:2024/12/25 01:14 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.38 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.09/-4.40
|
|
企业价值
37.56M
|
| 资产负债 |
|
每股账面净值
0.83
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
1.01
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2024/12/25 01:14 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |